DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes
Published version
Peer-reviewed
Repository URI
Repository DOI
Type
Other
Change log
Authors
Kizhakeyil, Atish
Zaini, Nurmahirah Binte Mohammed
Poh, Zhi Sheng
Wong, Brandon Han Siang
Loh, Xinpeng
Description
Funder: addenbrooke's charitable trust, cambridge university hospitals; doi: http://dx.doi.org/10.13039/501100002927
Keywords
Letter to the Editor, DDX3X mutation, Hematolymphoid malignancy, Prognosis, Tumour metastasis, Drug resistance
Is Part Of
Publisher
BioMed Central
Publisher DOI
Sponsorship
nanyang technological university (L0412290)
ministry of education - singapore (MOE2017-T2-2-004)
national medical research council (OFLCG18May-0028, NMRC/TA/0051/2016)
kay kendall leukaemia fund (KKL649)
medical research council (MR/M008584/1)
wellcome trust (203151/Z/16/Z)
cancer research uk (A25117)
ministry of education - singapore (MOE2017-T2-2-004)
national medical research council (OFLCG18May-0028, NMRC/TA/0051/2016)
kay kendall leukaemia fund (KKL649)
medical research council (MR/M008584/1)
wellcome trust (203151/Z/16/Z)
cancer research uk (A25117)